Milsaperidone (VHX-896) vs Paliperidone palmitate (Invega Sustenna)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Paliperidone palmitate (Invega Sustenna)
Marketed by Johnson & Johnson
NCT00101634 · Phase 3 · completed
The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint.
Next expected readout: December 2026 · NCT07493551 (registry estimate)
Reported efficacy
Part-2 (Disease Progression): Time to First Treatment Failure (From Day 1 up to 9 Months); Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and 18 Months); Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and Day 260): Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). (missed)
Result source: NCT02431702
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Paliperidone palmitate (Invega Sustenna) |
|---|---|---|
| PANSS total, change | —Not reported | -13.2 vs -2.9−10.3 vs placeboNCT0059057716 other results
|
| CGI-S, change | —Not reported | -1 vs 0−1 vs placeboNCT0059057719 other results
|
| PANSS response | —Not reported | —Not posted · NCT00101634 |
| PSP, change | —Not reported | 8.3 vs 1.7+6.6 vs placeboNCT0059057716 other results
|
| Relapse (% of patients) | —Not reported | —Not posted · NCT00101634 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone palmitate (Invega Sustenna)
- -13.2 vs -2.9−10.3 vs placeboNCT00590577
16 other results
- -11.6 vs -2.9 NCT00590577
- -8 vs -2.9 NCT00590577
- -18.6 vs -17.9 NCT00589914
- -25.5 vs -24.6 NCT01081769
- -24.3 vs -23.7 NCT01081769
- -23.5 vs -22.8 NCT01081769
- -21.7 vs -21.9 NCT01081769
- -1.8 vs -1.6 NCT03345342
- -21.8 vs -21.2 NCT01081769
- -19.5 vs -20.1 NCT01081769
- -18.5 vs -18.6 NCT01081769
- -16.2 vs -16.8 NCT01081769
- -14.5 vs -15 NCT01081769
- -12.2 vs -12.3 NCT01081769
- -9.4 vs -8.8 NCT01081769
- -4.8 vs -3.7 NCT01081769
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone palmitate (Invega Sustenna)
- -1 vs 0−1 vs placeboNCT00590577
19 other results
- -1 vs 0 NCT00590577
- -1 vs 0 NCT00590577
- -1.1 vs -1.1 NCT01081769
- -1 vs -1.1 NCT01081769
- -1 vs -1 NCT01081769
- -0.9 vs -1 NCT01081769
- 0 vs 0 NCT03345342
- -1 vs -1 NCT01081769
- -0.9 vs -0.9 NCT01081769
- -0.8 vs -0.8 NCT01081769
- -0.7 vs -0.8 NCT01081769
- -0.6 vs -0.6 NCT01081769
- -0.9 vs -0.9 NCT00589914
- -0.4 vs -0.5 NCT01081769
- -0.3 vs -0.3 NCT01081769
- -0.1 vs -0.1 NCT01081769
- -0.2 vs -0.3 NCT02431702
- -0.7 vs -0.7 NCT02431702
- -0.5 vs -0.4 NCT01157351
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone palmitate (Invega Sustenna)
- —Not posted · NCT00101634
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone palmitate (Invega Sustenna)
- 8.3 vs 1.7+6.6 vs placeboNCT00590577
16 other results
- 6.1 vs 1.7 NCT00590577
- 2.9 vs 1.7 NCT00590577
- 15.2 vs 14.6 NCT01081769
- 14.7 vs 14 NCT01081769
- 14 vs 13.3 NCT01081769
- 12.9 vs 12.9 NCT01081769
- 1 vs 1.1 NCT03345342
- 12.7 vs 12.3 NCT01081769
- 11.4 vs 11.9 NCT01081769
- 9.9 vs 10.8 NCT01081769
- 7.6 vs 7.7 NCT01081769
- 8.5 vs 8.8 NCT00589914
- 4.9 vs 4.3 NCT01081769
- 7.5 vs 7 NCT02431702
- 2.5 vs 2.9 NCT02431702
- 5.8 vs 5.4 NCT01157351
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone palmitate (Invega Sustenna)
- —Not posted · NCT00101634
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Paliperidone palmitate (Invega Sustenna): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Paliperidone palmitate (Invega Sustenna) |
|---|---|
| Dropout rate | —Part 2-Paliperidone Palmitate (PP)a NCT02431702 · Phase 3 show 16 more results—Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 59.6% NCT01157351 · Phase 4 · registry result, not featured evidence —Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 —Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 6.4% NCT01081769 · Phase 3 · registry result, not featured evidence 40.3%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence —Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 24.8% NCT00589914 · Phase 3 · registry result, not featured evidence 44.8%150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 46.1%100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 48.1%25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 28.6%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 21.4%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 14.3%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —Part 2-Paliperidone Palmitate (PP)a NCT02431702 · Phase 3 show 16 more results—Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 2.2% NCT01157351 · Phase 4 · registry result, not featured evidence —Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 —Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 — NCT01081769 · Phase 3 · registry result, not featured evidence 17%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence —Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 3.1% NCT00589914 · Phase 3 · registry result, not featured evidence 8%150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 6.1%100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 6.3%25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.8%Part 2-Paliperidone Palmitate (PP)a NCT02431702 · Phase 3 show 16 more results5.3%Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 2%Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 18.6% NCT01157351 · Phase 4 · registry result, not featured evidence 5%Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 5.5%Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 11.2% NCT01081769 · Phase 3 · registry result, not featured evidence 6.3%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence 3.9%Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 6.8% NCT00589914 · Phase 3 · registry result, not featured evidence —150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence —100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence —25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 14.3%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 21.4%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 16 more resultsinjection site pain 18.6% insomnia 18.6% weight increased 13.3% NCT01157351 · Phase 4 · registry result, not featured evidence weight increased 8.4% injection site pain 7.7% headache 6.7% NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 nasopharyngitis 3.7% upper respiratory tract infection 0.9% headache 0% NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 weight increased 15.4% insomnia 11.2% headache 10.6% NCT01081769 · Phase 3 · registry result, not featured evidence insomnia 17% (placebo 15.2%) injection site pain 13.2% (placebo 6.7%) nasopharyngitis 12.6% (placebo 6.1%) NCT01299389 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.4% (placebo 6.1%) constipation 5.2% (placebo 5.5%) insomnia 3.9% (placebo 15.2%) NCT01299389 · Phase 3 · registry result, not featured evidence insomnia 9.4% headache 7.1% somnolence 5.6% NCT00589914 · Phase 3 · registry result, not featured evidence 150 mg eq. injection site pain 8% (placebo 3.7%) headache 6.1% (placebo 7.3%) akathisia 5.5% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 100 mg eq. headache 6.7% (placebo 7.3%) injection site pain 6.1% (placebo 3.7%) akathisia 4.8% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 25 mg eq. headache 10.6% (placebo 7.3%) injection site pain 8.8% (placebo 3.7%) akathisia 1.3% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 150 mg blood prolactin increased 92.9% insomnia 28.6% nasopharyngitis 28.6% NCT01606254 · Phase 2 · registry result, not featured evidence 100 mg blood prolactin increased 64.3% psychiatric symptom 42.9% nasopharyngitis 28.6% NCT01606254 · Phase 2 · registry result, not featured evidence 150/ 50 mg blood prolactin increased 71.4% nasopharyngitis 28.6% alanine aminotransferase increased 21.4% NCT01606254 · Phase 2 · registry result, not featured evidence 50 mg blood prolactin increased 78.6% nasopharyngitis 35.7% psychiatric symptom 35.7% NCT01606254 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 15 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Paliperidone palmitate (Invega Sustenna)
show 2 more results
show 3 more results
show 16 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 19 more results
+ 19 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Paliperidone palmitate (Invega Sustenna)'s landscape